If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma highlights expanded services platform

    Quick Contact
    • Aptar Pharma
    Aptar Pharma highlights expanded services platform

    Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting at CPhI Worldwide 2019, the world’s largest pharmaceutical exhibition, which will take place November 5-7 in Frankfurt, Germany. More than 45,000 visitors and 2,500 international exhibitors are expected to attend this year’s three-day event.

    At Stand 111D70, Aptar Pharma will be featuring its diverse portfolio of drug delivery systems, components and active packaging solutions, including their latest innovations addressing nasal, pulmonary, eye care, injectables and dermal drug delivery routes including:

    • PureHale – a revolutionary, portable and ready-to-use device designed to deliver natural care to upper airways
    • A dedicated Connectivity hub will host Aptar Pharma’s expanding range of connected drug delivery devices and show how Aptar is building a connected devices eco-system for digital medicines
    • Nanopharm’s SmartTrackTM - a novel approach to decrease program costs and avoid BE studies in OINDPs. SmartTrackTM will also be a featured stop on CPhI’s guided Innovation Tours on November 6 and 7, and has been entered in the 2019 CPhI Pharma Awards.

    Aptar Pharma’s newly expanded Aptar Pharma Services platform will be introduced at this year’s CPhI. Offering early stage to commercialization services, Aptar Pharma has over 25 years’ experience supporting regulatory submissions. Leading experts from Aptar Pharma’s analytical services companies will be on hand to discuss how their value-added services can help customers accelerate and derisk their drug development journey:

    • Nanopharm, a leading provider of orally inhaled and nasal drug product design and development services.
    • Next Breath, a full-service cGMP lab specializing in analytical testing of drug delivery systems
    • Gateway Analytical, providing industry-leading particulate detection and predictive analytical services

    Aptar CSP Technologies, part of the Aptar family, will be presenting their extensive portfolio of active packaging solutions including the award-winning XcelerateTM Development Services which can help expedite time-to-market for moisture- and oxygen-sensitive drugs.

    Several of Aptar Pharma’s Injectables initiatives will also be featured. Aptar Pharma QuickStartTM – a sterile, ready-to-use early stage injectable development package now available for purchase on aptar.com/pharma. QuickStartTM is designed to accelerate and derisk time-to-market for start-ups, R&D, biotechs and university research organizations. Also, discover Aptar Pharma’s Injectable plans underway for expanding production capabilities and capacity worldwide.

    On Wednesday, November 6, Aptar Pharma experts will present three back-to-back Pharma Insight Briefings, outlining the latest trends and technologies:

    • “Driving Foreign Particulate Analysis: How to Choose Between Manual and Automated” (13:50-14:20). Presented by David Exline, President, Gateway Analytical, an Aptar Pharma company
    • “Advantages of Nasal Powders for Drug Repurposing” (14:30–15:00). Presented by Dr Gerallt Williams, Director Scientific Affairs, Aptar Pharma
    • “Beyond Pharmaceutical Packaging: New Solutions to Old Challenges” (15:10–15:40). Presented by Badre Hammond, Vice-President, Commercial Operations, Aptar CSP Technologies
    These Pharma Insight Briefings are free-to-attend and will take place at location 110D50 in the InnoPack & P-MEC Theatre.

    Aptar Pharma has been an exhibitor for many years at CPhI Worldwide, celebrating its 30th anniversary, bringing pharma professionals together to meet, discover and learn about the latest trends and ground-breaking ideas in the industry. Aptar Pharma welcomes the opportunity to once again demonstrate its wide-ranging expertise and latest drug delivery technologies, and meet with customers to see how Aptar can help meet their next drug delivery challenge.

    Image: PureHale

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Jo Webb
    • Product Info
    • English
    • Created 07 Oct 2019
    • Modified 07 Oct 2019
    • Hits 914
    Sun-Rain
    APG
    Epopack